Skip to main content

S1P Modulator Deal Benchmarks in Gastroenterology

Median Upfront
$586M
Range: $312M - $852M
Total Deal Value
$3.0B
Range: $1.9B - $4.1B
Royalty Rate
7.9% - 14.7%
Tiered up to 18.7%
Dev Milestones
$509M
Range: $333M - $687M
Model Your Deal

Market Analysis

S1P Modulator therapies in gastroenterology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 s1p modulator asset in gastroenterology is $586M, with total deal values reaching $3.0B. Development milestones average $509M, while regulatory milestones contribute $606M.

The gastroenterology s1p modulator landscape is characterized by moderate-to-high competitive intensity concentrated in IBD and eosinophilic GI disorders. TL1A inhibitors, gut-selective integrins, and S1P modulators are broadening the therapeutic toolkit beyond TNF and integrin blockade. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for s1p modulator gastroenterology deals range from 7.9% to 14.7% at the base tier, with tiered escalation reaching 11.9%-18.7% on blockbuster sales. Commercial milestones averaging $1.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a s1p modulator gastroenterology licensing deal?
Based on our analysis, Phase 2 s1p modulator licensing deals in gastroenterology average $586M in upfront payments, with a range of $312M to $852M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for s1p modulator gastroenterology transactions?
The median total deal value for Phase 2 s1p modulator assets in gastroenterology is $3.0B, ranging from $1.9B to $4.1B. This includes development milestones ($509M), regulatory milestones ($606M), and commercial milestones ($1.3B).
What royalty rates are standard for s1p modulator deals in gastroenterology?
Base royalty rates for s1p modulator gastroenterology transactions range from 7.9% to 14.7%, with tiered escalations reaching 11.9%-18.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in s1p modulator gastroenterology deals?
S1P Modulator gastroenterology deals allocate approximately 81% of total deal value to milestones. Development milestones ($509M) make up the largest share, followed by commercial milestones ($1.3B) and regulatory milestones ($606M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Gastroenterology

View

Monoclonal Antibody in Gastroenterology

View

S1P Modulator in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included